5-ethyl-4-hydroxy-6-(2-((4-isopropylpiperazin-1-yl)methyl)-1-methyl-1H-indol-5-yl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid | 1426525-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-ethyl-4-hydroxy-6-(2-((4-isopropylpiperazin-1-yl)methyl)-1-methyl-1H-indol-5-yl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
• 英文别名: 5-ethyl-4-hydroxy-6-[1-methyl-2-[(4-propan-2-ylpiperazin-1-yl)methyl]indol-5-yl]-2-oxo-1H-pyridine-3-carboxylic acid
• CAS: 1426525-46-3
• 化学式: C₂₅H₃₂N₄O₄
• 分子量: 452.553
• InChiKey: FDRQPOIJYVAPHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  98
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS MÉTHODES D'UTILISATION
  申请人：PTC THERAPEUTICS INC

  公开号：WO2013033258A1

  公开（公告）日：2013-03-07

  The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

  本文描述了化合物、形式及其制药组合物以及使用方法，用于治疗或缓解由野生型和多重耐药革兰氏阴性和革兰氏阳性病原体引起的细菌感染。
• ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE
  申请人：PTC THERAPEUTICS, INC.

  公开号：US20150038437A1

  公开（公告）日：2015-02-05

  The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

  本说明涉及化合物和形式以及其制药组合物，以及使用它们治疗或改善由野生型和多重耐药革兰氏阴性和革兰氏阳性病原体引起的细菌感染的方法。
• Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
  申请人：The Regents of the University of California

  公开号：US10927160B2

  公开（公告）日：2021-02-23

  Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.

  所公开的是利用造血干细胞和祖细胞（HSPCs）工程化的不变自然杀伤T（iNKT）细胞及其制造和使用方法。具体地说，iNKT 工程细胞经过基因修饰，含有至少一种外源不变自然杀伤 T 细胞受体（iNKT TCR）核酸分子。进一步公开的是 iNKT TCR 核苷酸序列和用于表达的密码子优化序列。
• METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP3164713A1

  公开（公告）日：2017-05-10
• SYSTEMIC GLUCOSE TOLERANCE IN TYPE-2 DIABETES
  申请人：Qi Ling

  公开号：US20140193361A1

  公开（公告）日：2014-07-10

  Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeostasis in mice at different stages of obesity. Accordingly, the present invention provides methods of treating type-2 diabetes or those at risk for type-2 diabetes using activators of adipose-resident NKT cells. Such activators include particular glycolipids (e.g., a-galactosyl-ceramide and its analogs other than sulfated analogs) and cytokines that promote M2 macrophage polarization. The invention also includes methods to screen for activators of adipose-resident NKT cells.